Exelixis
EXEL
#1695
Rank
HK$77.41 B
Marketcap
HK$271.08
Share price
0.52%
Change (1 day)
66.21%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total debt

Total debt on the balance sheet as of September 2024 : HK$1.51 Billion

According to Exelixis's latest financial reports the company's total debt is HK$1.51 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Exelixis - Total debt on balance sheet (from 2000 to 2024)

Total debt by year

Year Total debt Change
2023-12-31HK$1.48 B-0.16%
2022-12-31HK$1.48 B271.65%
2021-12-31HK$0.39 B5.06%
2020-12-31HK$0.38 B1.77%
2019-12-31HK$0.37 B220.12%
2018-12-31HK$0.11 B0.08%
2017-12-31HK$0.11 B-92.04%
2016-12-31HK$1.46 B-54.73%
2015-12-31HK$3.23 B16.99%
2014-12-31HK$2.76 B2.83%
2013-12-31HK$2.69 B3.47%
2012-12-31HK$2.60 B84.59%
2011-12-31HK$1.40 B-13.1%
2010-12-31HK$1.62 B162.79%
2009-12-31HK$0.61 B-32.12%
2008-12-31HK$0.90 B-4.02%
2007-12-31HK$0.94 B0.14%
2006-12-31HK$0.94 B-18.02%
2005-12-31HK$1.15 B0.78%
2004-12-31HK$1.14 B32.99%
2003-12-31HK$0.86 B49.34%
2002-12-31HK$0.57 B51.08%
2001-12-31HK$0.38 B227.3%
2000-12-31HK$0.11 B12.85%
1999-12-31HK$0.10 B

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
HK$167.27 B 10,953.10%๐Ÿ‡ฌ๐Ÿ‡ง UK
HK$198.16 B 12,994.04%๐Ÿ‡ซ๐Ÿ‡ท France
HK$296.77 B 19,510.17%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$400.04 B 26,334.21%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$470.08 B 30,961.74%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$278.25 B 18,286.18%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$518.48 B 34,160.07%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$27.69 M-98.17%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$0.30 B-80.11%๐Ÿ‡บ๐Ÿ‡ธ USA